
    
      About 2,000 eNSCLC patients who received radical resection from about 50 research centers
      across the country will be included in this study, and will be followed up to 2 years after
      enrollment according to the actual clinical situation. The analysis method of this study is
      mainly based on descriptive statistics. The information about the human genetic resources of
      the subjects to be collected includes: demography, physical examination, WHO fitness status,
      medical history, smoking history, disease characteristics, surgical information, initial and
      follow-up adjuvant treatment pattern, laboratory tests, survival status, and adverse events
      related to gefitinib/osimertinib, serious adverse events/non-severe ADR, measures taken for
      adverse events, outcome of adverse events.
    
  